Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQB2930 alone or in combination for HER2-positive recurrent or metastatic breast cancer
CTR20231777Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2930 in breast cancer, Nonhematologic neoplasms, sponsored by Nanjing Shunxin Pharmaceutical. Started Apr 2023; status: active.
02
Drugs
TQB2930
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20231777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231777.